The British Journal of Psychiatry 137: 440-443 (1980)
© 1980 The Royal College of Psychiatrists
Viloxazine in the treatment of depressive neurosis: a controlled clinical study with doxepin and placebo
JP McEvoy, WF Sheridan, WR Stewart Jr, TA Ban, WH Wilson, W Guy and JD Schaffer
In a four-week, double-blind, clinical trial thirty-one patients with
depressive neurosis were treated with viloxazine, doxepin, or placebo.
There were no differences among the three groups in therapeutic effects.
Many depressed out-patients improve on placebo. Viloxazine hydrochloride is
one of a series of compounds developed to explore the central nervous
system activity of the aryloxypropanolamine type of beta-adreno-receptor
antagonists. Initial clinical study support the hypothesis that viloxazine
has antidepressant properties in man (Bayliss et al, 1974; Bereen, 1973;
Pichot et al., 1975; Tsegos and Ekdawi, 1974).